# Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

> **NCT05498272** · PHASE2 · RECRUITING · sponsor: **Rana McKay, MD** · enrollment: 32 (estimated)

## Conditions studied

- Prostate Cancer
- BRCA1 Mutation
- BRCA2 Mutation
- Prostatic Adenocarcinoma
- High-Risk Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** LHRH agonist

## Key facts

- **NCT ID:** NCT05498272
- **Lead sponsor:** Rana McKay, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2026-03
- **Final completion:** 2026-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498272, "Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT05498272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*